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Abstract    
 
Background  
Naturally hypoxic conditions in amniote embryos play important roles in normal 
development. We previously showed that a hypoxic condition is required to produce a 
sufficient amount of neural crest cells (NCCs) during embryogenesis and that 
promoting a hypoxic response by prolyl-hydroxylase (PHD) inhibitors increases NCCs. 
Given that PHD inhibitors are considered as a potential treatment for anaemia and 
ischemic diseases, we investigated the phenotypic effect of PHD inhibitors on 
embryonic development. 
 
Methods 
Chick embryos were administered with PHD inhibitors prior to the induction of NCCs 
on day 1.5. Three main events relating to hypoxia, NCCs induction, vasculogenesis 
and chondrogenesis, were examined. 
 
Results 
PHD inhibitors caused an increase of Sox10-positive NCCs in vivo. Vasculogenesis 
was promoted temporarily, although rapid vasculogenesis diminished the effect by day 
5 in cephalic and pharyngeal regions. Studies on chondrogenesis at day 7 showed 
advanced development of the otic capsule, a cartilaginous structure encapsulating the 
inner ear. Analysis by X-ray micro-computed-tomography (µCT) revealed smaller otic 
capsule, suggesting premature differentiation. This in turn deformed the developing 
semicircular canals within it. Other skeletal structures such as the palate and jaw were 
unaffected. The localised effect on the otic capsule was considered a result of the 
multiple effects from the hypoxic responses, increased NCCs and promoted 
chondrogenesis.  
 
Conclusion 
Given the wide range of clinical applications being considered for PHD inhibitors, this 
study provides crucial information to caution and guide use of PHD inhibitors when 
treating women of childbearing age. 
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Introduction 
The skeletal structure of the vertebrate head originates from both neural crest 
cells (NCCs) and head mesoderm  (Abzhanov and others, 2007; Couly and others, 
1993; Noden and Trainor, 2005; Santagati and Rijli, 2003). A deficit of cranial NCCs 
may result in congenital craniofacial hypoplasia and facial distortion. Genetic 
conditions such as Treacher Collins, DiGeorge and CHARGE syndromes and Pierre 
Robin sequence, as well as non-hereditary conditions such as fetal alcohol syndrome 
and retinoid embryopathy, are all attributed to NCC defects  (Ahlgren and others, 2002; 
Bajpai and others, 2010; Cartwright and Smith, 1995; Escot and others, 2016; Kiecker, 
2016; Rovasio and Battiato, 1995; Tan and others, 2013; Trainor, 2010). NCCs arise 
from the dorsal neural tube during early embryogenesis by epithelial-mesenchymal 
transition (EMT) and differentiate not only to neural and pigmental cells but also to 
facial bones, cartilages and connective tissues among others, providing the skeletal 
basis for the head and neck structures together with mesodermal cells (Le Douarin and 
Kalcheim, 1999). 
Induction, proliferation, migration and differentiation of NCCs are controlled at 
multiple steps by a gene regulatory network (Simoes-Costa and Bronner, 2015). In 
addition to the genetic control, we have recently found that the naturally occurring 
embryonic hypoxia contributes to the induction of NCCs (Scully and others, 2016), 
providing a new insight into the mechanism for normal development and new strategies 
to tackle NCC defects. Under hypoxic conditions, a transcription factor Hypoxia-
Inducible Factor (HIF) permits cell adaptation by promoting cell survival, through 
anaerobic glycolysis and angiogenesis, as well as increased EMT (Semenza, 2014). 
In adult pathological conditions, this mechanism aids ischaemic tissue recovery, 
however, it too aids the promotion of cancer progression and metastasis. In normoxia, 
on the other hand, α-subunit of HIF (HIFα) is hydroxylated at specific Proline residues 
by oxygen-dependent Prolyl-hydroxylase-domain-containing-enzymes (PHDs), a 
group of enzymes belonging to 2-oxoglutarate-dependent oxygenases (Bruick and 
McKnight, 2001; Markolovic and others, 2015). Hydroxylation of HIFα subsequently 
leads to its ubiquitination and degradation, hence the hypoxic response is blocked 
(Epstein and others, 2001). Because of this, PHD inhibitors have a great potential in 
ischemic disease therapies and are under rapid development (Thinnes and others, 
2015). While a number of PHD inhibitors are currently in clinical trials (Brigandi and 
others, 2016; Gupta and Wish, 2017; Provenzano and others, 2016; Yeh and others, 
2017), adverse effects such as erythrocytosis and cancer progression are also 
suggested, due to the role HIFα has in erythropoiesis, angiogenesis, cell survival, 
invasion and metastasis (McMullin, 2010; Semenza, 2010). As PHD inhibitors may well 
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be beneficial to pregnant females, for anaemia for example, the effect of the drugs on 
embryos needs investigation.   
Our previous study has shown that embryos exposed to relatively higher 
oxygen in the ex ovo condition shows reduced expression of Sox9/10 and Snail2 in 
the cranial NCCs population, and that application of PHD inhibitors restores it (Scully 
and others, 2016). The effect of PHD inhibitors was considered as an increase of EMT 
thus producing a larger amount of NCCs. It was also possible that expression of 
Sox9/10 genes, regulators of hypoxic response (Amarilio and others, 2007; Li and 
others, 2013), was enhanced in individual cells, and/or up-regulation of the HIF 
pathway by PHD inhibitors resulted in up-regulation of vascular endothelial growth 
factor (VEGF) (Krock and others, 2011; Nanka and others, 2006) which worked as a 
chemoattractant for NCCs (McLennan and others, 2010) thus promoting NCCs 
spreading. In either way, PHD inhibitors was able to restore NCCs defects in terms of 
Sox9/10 and Snail2 expression in embryos exposed to relatively high oxygen ex ovo. 
This raised a question as to whether PHD inhibitors exert a similar effect in vivo and, 
if so, whether they may be applicable to genetic diseases with NCC defects. To answer 
these questions we need to clarify whether PHD inhibitors give impact on all NCC 
derivatives or specific cell types, and whether they may cause any negative impact on 
development.   
One of the HIF target genes relevant to NCCs is Sox9 (Amarilio and others, 
2007; Zhang and others, 2011). Sox9 expression in the neural tube commits cells to 
undergo EMT, it then maintains cellular multipotency prior to lineage commitment 
(Cheung and Briscoe, 2003; McKeown and others, 2005). Sox9 also promotes 
chondrogenesis by inducing cartilage-specific extracellular matrix genes such as 
collagen type II (Akiyama and others, 2002; Amarilio and others, 2007; Bell and others, 
1997; Healy and others, 1999; Mori-Akiyama and others, 2003; Myllyharju and 
Schipani, 2010). Hence, the possible long-term impact that may arise by PHD inhibitors 
administration is enhanced chondrogenesis.  
Here we investigate the effect of PHD inhibitors in chick embryos grown in ovo 
for up to 10 days, using three PHD inhibitors; dimethyloxalylglycine (DMOG) (Elvidge 
and others, 2006), a glycine-linked dipeptidyl-quinolone derivative IOX2 (Chowdhury 
and others, 2013) and an 8-hydroxyquinoline 7-substituent CCT1 (Thinnes and others, 
2015). Following the application of the PHD inhibitors in ovo, increased expression of 
Sox10 was observed as previously seen ex ovo, suggestive of increased NCCs. 
Vasculogenesis was also promoted temporality. The prominent effect was on 
development of the otic capsule, a cartilaginous structure encapsulating the inner ear 
formed by contribution of NCCs. Detailed analyses using micro-computed tomography 
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(µCT) showed deformed otic capsule and semicircular canals. The rather localised 
phenotype may be due to the unique dual origin of the skull, NCCs and mesoderm, as 
well as two distinct ossification mechanisms, endochondral and intramembranous 
ossification. The structures affected by PHD inhibitors were limited to NCCs-derived 
cartilaginous parts. The study shows the multiple effects and specificity of PHD 
inhibitors on developmental processes in an amniote model and supports the need for 
further study of their potential teratogenic effects in mammals.  
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Methods 
 
Drug application in ovo, RNA in situ hybridisation, vessel labelling and Alcian 
blue staining 
Fertilised chicken eggs were incubated for 30 hours at 38°C to obtain  Hamburger and 
Hamilton stage (Hamburger and Hamilton, 1951) (HH) 5-6, opened with a window on 
the shell and injected with either DMSO (for control, Sigma), DMOG (Cayman), IOX2 
(Sigma) and CCT1 (provided by Prof. C. Schofield, Oxford). Compounds were 
dissolved in DMSO at 0.5 M for DMOG and 0.1 M for IOX2 and CCT1, which were 
further diluted in Hanks’ solution to 2 mM for DMOG and 0.2-0.8 mM for IOX2 and 
CCT1. Except for the evaluation experiment in Figure 1, compounds used for injection 
were DMOG 2 mM, IOX2 0.3 mM and CCT1 0.4 mM. DMSO was diluted at 1:250, the 
highest concentration used for drug dilution. Between 10-15 μl of the solution was 
injected in the space between the vitelline membrane and the blastoderm disk, using 
a mouth pipette. For administration at HH26, 25-30 μl of the solution was injected into 
the amniotic cavity. The window was sealed for continued incubation. Embryos were 
harvested and processed at required stages. RNA in situ hybridisation for Sox10 
(Cheng and others, 2000) was performed as previously described (Scully et al., 2016). 
Vessels were labelled by injecting with Lectin Lens culinaris Agglutinin (LCA) 
conjugated with rhodamine (Vector) by heart perfusion immediately before fixing with 
4% paraformaldehyde. After removing the heart, embryos were flat-mounted. Alcian 
blue staining was performed as described (Behringer, 2014). 
 
µCT scanning 
Embryos were harvested 9 days post drug-application, washed in PBS and transferred 
to 4% paraformaldehyde in PBS overnight at 4°C. After washing with PBS, embryos 
were dehydrated with ethanol in a graded manner (50%, 70%, 90% and 100% twice) 
over a few hours, followed by staining with 1% Iodine in 100% ethanol overnight. 
Embryos were washed with 100% ethanol for 2 hours before scanning. CT images 
were obtained by scanning the embryos placed in a falcon tube with no solution. Scans 
were conducted on a Nikon XTH225ST CT scanner, using settings within the following 
ranges 70-80kV, 98-156uA, and 1000-1415 exposure times. Between 2000 and 3141 
projections were taken, and most scans also averaged two frames per projection, 
resulting in scan lengths of up to 100 minutes. The variation in settings applied was a 
result of seeking optimal conditions for the best resulting tomograms in the time 
available, primarily to minimise noise in the resulting datasets. The projections were 
reconstructed using CT Pro 3D, resulting in TIF stacks of tomographic slices revealing 
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internal structures with voxel sizes of between 9.07 and 12.50 microns. VG Studio Max 
3.0  (https://www.volumegraphics.com/) was utilised to reorient the tomogram slices 
into anatomical orientation, and to apply median filtering (size 3) to reduce noise in the 
slices (the latter applied only to the scans used for 3D reconstructions). Finally, the 3D 
visualisations of the otic capsule and inner ear were segmented out using a 
combination of semi-automated and manual segmentation tools in Avizo 8.1 software 
(https://www.fei.com/software/amira-avizo/). 3D models, Raw scan data and settings 
are available on 
https://data.bris.ac.uk/webshare/microCT_of_chick_embryonic_head/d317c0f5-5543-
431b-aa6c-f08351b73883/. Further details and exact scan parameters in each case 
are provided in the readme.txt file accompanying the above datasets. SPSS software 
was used for ANOVA analyses. 
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Results  
 
PHD inhibitors increase neural crest cells in ovo 
To examine the effect of PHD inhibitors on NCCs in physiological conditions, 
each of DMOG, IOX2 and CCT1 as well as control DMSO, was applied in ovo at the 
head-fold stage (HH5-6, embryonic day (E) 1.5). The optimum concentration for IOX2 
and CCT1 was empirically established by assessing Sox10 expression at HH12 
showing intense Sox10 staining in NCCs compared to DMSO-treated embryos (Fig. 
1), and was used throughout this study (see Methods). We found stronger staining of 
Sox10 in NCCs at all cranial levels, similar to what was observed with DMOG in our 
previous ex ovo studies (Scully and others, 2016). The phenotype is likely due to 
augmented EMT that increased the number of neural crest cells as suggested 
previously (Scully and others, 2016). It is also possible that individual cells expressed 
Sox10 more strongly as a regulator of hypoxic response (Li and others, 2013).  
 
PHD inhibitors promote vasculogenesis  
One of the major hypoxic responses in adults is angiogenesis that increases 
the local oxygen supply. In mouse embryos, HIF1α is required for proper vasculature 
development (Iyer and others, 1998; Ryan and others, 1998). It is also known in chick 
embryos that hypoxia upregulates the expression of VEGF and subsequent 
vasculogenesis (Nanka and others, 2006). In agreement with these, application of 
PHD inhibitors at HH5-6 promoted vasculogenesis as an immediate effect (Fig. 2). In 
normal embryogenesis, a pair of longitudinal dorsal aortae develop by HH12, which 
later fuse at the midline by a balance of signals including VEGF-A, forming the 
descending aorta (Garriock and others, 2010). It was noticed that PHD inhibitor-treated 
embryos tend to show fused dorsal aortae by HH12 at the level of the vitelline veins, 
the inflow tract to the heart (Fig. 2A-D), suggesting advanced vascular development. 
The width of the dorsal aortae tended to be greater in drug-treated embryos, however 
due to the natural variability along the vessels, it was not possible to quantify the width 
accurately. At HH13, the cephalic plexus begins to develop in the mesencephalon 
(Coffin and Poole, 1988) and drug-treated embryos showed higher density of the 
network (Fig. 2E-H). At HH25, however, the vessels and capillaries have developed in 
a dense manner in both control and drug-treated embryos and there was no apparent 
difference between them (Fig. 3A-J). Because of the recovered vessel phenotype in 
cephalic and pharyngeal regions at HH25, it appeared that the transiently increased 
vasculogenesis was not consolidated as a phenotype at a later stage, probably due to 
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the rapid and dynamic development of vasculogenesis by various regulatory 
mechanisms, including HIF as well as others (Ferguson and others, 2005). 
In contrast to cephalic and pharyngeal levels, the trunk level between upper 
and lower limbs is yet to be formed when the drugs were applied at HH5-6. It was 
noted that, three days after the drug application (HH25), the developing trunk showed 
advanced vasculatures in embryos treated with PHD inhibitors (Fig. 3K-O), suggesting 
that the drug remained effective at least 3 days after the application and had worked 
on newly emerging structures.   
 
PHD inhibitors promote chondrogenesis of the otic capsule 
Next, the effect of PHD inhibitors on chondrogenesis was examined by Alcian 
blue staining (Fig. 4). The otic capsule arises as a cartilaginous structure located in the 
posterior-lateral aspect of the cranium, which eventually ossifies and provides 
protection to the inner ear located within it. The origin of the otic capsule is contentious 
(Gross and Hanken, 2008) but it is likely a mix of both NCCs (Le Lievre, 1978; Noden, 
1983; O'Gorman, 2005) and head mesoderm (Couly and others, 1992). The inner ear, 
on the other hand, originates from the otic vesicle, which separates as the otocyst from 
the otic placode at HH18 (E3) (Chang and others, 2002). Small pouches start to 
develop at HH23-27 (E4-E5), which rapidly develop to loops at HH28-31 (E6-E7), thus 
forming superior (anterior), posterior and horizontal (lateral) semicircular canals 
(Bissonnette and Fekete, 1996; Chang and others, 1999). Such formed membranous 
labyrinth serves as a template of the inner ear when chondrogenesis occurs in the 
surrounding mesenchyme to form the otic capsule (Fig. 4A-F) (Chang and others, 
1999; Chang and others, 2002; McPhee and Van de Water, 1986).  
At HH30, embryos treated with PHD inhibitors at HH5-6 exhibited the structure 
of the otic capsule to be more complex compared to controls, resembling that of later 
stages (Fig. 4A-I). Three outpouches, the primordia of three semicircular canal aspects 
of the capsule, showed more advanced morphology, suggesting that PHD inhibitors 
caused accelerated development of the otic capsule. As HH30 was 5 days after the 
application of PHD inhibitors, it was not certain as to whether the drugs remained active 
and directly worked on chondrogenesis. To test the direct effect of the drugs, they were 
applied to embryos at HH26, immediately before the onset of chondrogenesis. 
Embryos treated with PHD inhibitors at HH26 showed advanced complexity of the otic 
capsule compared to the control (Fig. 4J-M), similarly to the ones with earlier injections, 
supporting the possibility that the drugs injected at HH5-6 have remained in the embryo 
and directly contributed to the advanced development of the otic capsule. The 
sustaining effect of the drug was in agreement with the result of promoted 
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vasculogenesis in the late-developing trunk region at HH25 suggesting the stability 
and bioactivity of the drugs in vivo at HH25. 
 
The structure of the otic capsule is altered by PHD inhibitors  
Due to the deep location and complex three-dimensional structure of the otic 
capsule, X-ray µCT scans were employed next. On HH36 (E10) chick embryos, it 
enabled image segmentation and 3D visualisation of the in situ structure of the otic 
capsule within the skull (Fig. 5). The application of DMOG was shown to significantly 
decrease the maximum width of the otic capsule (Fig. 5J) as well as the height (Fig. 
5C,D). Changes to the dimensions of the otic capsule have distorted the inner ear lying 
within it (Fig. 6). The height of the anterior semicircular canal was reduced significantly 
in DMOG-treated embryos (Fig. 6K). The effect of CCT1 on the dimensions of the otic 
capsule and anterior semicircular canal also looked prominent but statistically not quite 
significant (see the legend of Figs. 5,6). Nonetheless, both CCT1 and IOX2 caused 
noticeably thinner semicircular canals compared to DMSO controls (Fig. 6E-H) 
presumably by compression by the surrounding otic capsule. Thus, although advanced 
development of the otic capsule was seen at E7 (Fig. 4), semicircular canals at HH36 
were deformed and small in size. This is likely due to the nature of chondrogenesis, 
where matrix deposition would limit further morphogenesis. Based on these results, it 
was suggested that PHD inhibitors caused accelerated and premature chondrogenesis 
of the otic capsule. 
As development of the otic capsule is under the influence of BMP signals 
emanating from the otic vesicle (Chang and others, 2002), the expression of Msx1, a 
target gene for BMP signals (Suzuki and others, 1997), was examined in embryos 
treated PHD inhibitors. There were not obvious changes observed for Msx1 expression 
(Supplementary Fig. 1), ruling out a possible involvement of BMP signals in premature 
chondrogenesis caused by PHD inhibitors. 
 
The formation of the palate and other cartilaginous structures are not affected 
by PHD inhibitors 
Given the impact of PHD inhibitors on development of the otic capsule, we 
further examined development of other skeletal structures in the cranium. In contrast 
to the effect on the otic capsule, administration of PHD inhibitors at HH5-6 did not show 
apparent changes in the nasal capsule, Meckel’s cartilage or tongue cartilages that 
had developed by HH34-36 (E8-10) (Supplementary Fig. 2). X-ray µCT analyses 
revealed that the maxilla and mandible as well as the structure of the eye were largely 
normal in all drug-treated embryos (Fig. 7A-D). We  analysed in detail the palate, which 
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arises from NCCs and has a slit called the internal naris, similar to mammalian cleft 
palate; however, no significant change was found in drug-treated embryos (Fig. 7E,F).  
Thus, the impact PHD inhibitors have in embryos is most prominent in the 
formation of the otic capsule, with transiently accelerated vasculogenesis. 
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Discussion 
 
Why is the long-term effect of PHD inhibitors localised to the otic capsule?  
In contrast to the increased expression of Sox10 in NCCs at all cranial levels 
at HH12 (E2) (Fig. 1), the effect of PHD inhibitors at HH30-36 (Fig. 4-7) was rather 
localised to the otic capsule. The reason for this may lie in the multiple roles of PHD 
inhibitors on development of NCCs and dual origin and ossification processes of the 
skull. At the pre-migratory stage, PHD inhibitors likely increase EMT of NCCs, which 
was revealed by increased expression of Snail2 (Scully and others, 2016). This might 
not be sufficient to cause drastic phenotypes in all NCC-derivatives, as further 
development of NCCs may compensate the increase during the proliferation, migration 
and differentiation processes, through interaction with the local environment and other 
NCCs (Carmona-Fontaine and others, 2008; Kulesa and Fraser, 2000; Noden, 1975; 
Noden and Trainor, 2005; Smith and others, 1997; Trainor and others, 2002). In order 
for PHD inhibitors to exert a structural effect, as well as promoting EMT of NCCs, it 
must also bias the cell fate of NCCs to that of a chondrocytic one and/or directly 
promote chondrogenesis itself. 
NCCs undergo cell fate commitment over a long time span during development. 
They have some levels of lineage restriction in the neural tube prior to emigration 
(Krispin and others, 2010; Schilling and Kimmel, 1994) while maintaining plasticity 
(Noden, 1986; Trainor and others, 2003). A direct target of HIF, Sox9/10, may have 
helped maintain NCCs in an undifferentiated state (Dravis and others, 2015; McKeown 
and others, 2005) and promote chondrogenesis at later stages (Amarilio and others, 
2007; Healy and others, 1999; Mori-Akiyama and others, 2003). The result of late-
stage administration of PHD inhibitors at HH26 in regards to the otic capsule 
phenotype was similar to the one caused by HH5-6 administration (Fig. 3), suggesting 
that PHD inhibitors are stable for at least 3 days and able to promote chondrogenesis 
as well as increasing NCCs. The promoted vasculature in the trunk region seen at 
HH25 further reinforced the stability of the drug. Thus, multiple functions of PHD 
inhibitors at different stages of NCCs development are the key to cause the embryonic 
phenotype. 
Facial and cranial vault structures arise from NCCs and paraxial mesoderm, 
and many ossify either endochondrally or intramembranously, while others remain as 
cartilage (Abzhanov and others, 2007; Couly and others, 1993; Noden and Trainor, 
2005; Percival and Richtsmeier, 2013). Thus, only a limited number of bony structures, 
including the otic capsule, are formed with NCCs and undergo chondrogenesis for 
endochondral ossification. For example, the palate is a derivative of NCCs and 
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undergoes intramembranous ossification, thus PHD inhibitors would not work on the 
differentiation step, which may be the explanation why it was not affected by PHD 
inhibitors as seen in Figure 7.  
Other structures that arise from NCCs and undergo chondrogenesis include 
the sclera, nasal capsule, Meckel’s cartilage, columera, quadrate and hyoid, although 
some are contentious (Bellairs and Osmond, 2005; Le Douarin and Kalcheim, 1999). 
However, we did not find obvious effect of PHD inhibitors on nasal capsule, sclera and 
Meckel’s cartilage at HH34-36 (supplementary Figure 2). With regard to the sclera and 
nasal capsule, this may be because of the fact that these structures persist as cartilage 
until postnatal or adulthood, which is different from most embryonic cartilage elements 
that are eventually replaced by bones relatively quickly. Interestingly, the chondrogenic 
differentiation process takes much longer in the sclera compared to that of limb, that 
allows sclera to adapt to the rapid growth of the eye while providing physical rigidity 
(Thompson and others, 2010). A similar rule may apply to the nasal capsule that 
changes the shape dramatically after pneumatisation (Smith and others, 2008). Hence, 
these cartilages in chick might be relatively refractory to factors that cause premature 
differentiation as was observed in the otic capsule. This is in contrast to the otic 
capsule, which grows very rapidly and develops morphological complexity in a short 
period of time at HH14-31 (Bissonnette and Fekete, 1996; Chang and others, 2002). 
Therefore, the timing and speed of organ development may be crucial for the 
susceptibility to the drugs, which is a common feature on critical period to teratogens.  
It is to note that Waardenburg syndrome patients with Sox10 mutations present 
enlarged vestibule and bilateral agenesis or hypoplasia of semicircular 
canals (Elmaleh-Berges and others, 2013; Sznajer and others, 2008). Sox10 
heterozygous mouse embryos are known to present reduced NCCs and migration 
problem (Southard-Smith and others, 1998). While the present study concerns 
embryos with increased Sox10 expression, both studies highlight that the inner ear is 
sensitive to the Sox10 expression level in the NCCs population. 
 
Future perspective 
Although physiological hypoxia is required for normal development of NCCs 
(Scully and others, 2016), this study has demonstrated that excess activation of the 
hypoxic pathway can have adverse effect on inner ear development. The adverse 
effect of PHD inhibitors on embryogenesis is important to note for the future clinical 
application of the drugs to childbearing women, given that PHD inhibitors are currently 
considered to be applicable to a wide range of ischemic diseases including renal 
anaemia (Brigandi and others, 2016; Maxwell and Eckardt, 2016; Provenzano and 
 15
others, 2016). In humans, the otocyst begins to form semicircular canals at the 5th week 
of gestation, that becomes surrounded by cartilaginous otic capsule by week 8, while 
early ossification begins after 20 weeks (Anson and Bast, 1958). The longer gestation 
period in human may suggest a lower chance of suffering from multiple effects of the 
drug, although it depends on its stability. It is yet to clarify whether or not a single effect 
of PHD inhibitors, e.g. an increase of NCCs alone, would have a long-term impact. It 
is also interesting to know whether the increase of NCCs by PHD inhibitors would have 
a rescuing effect on model animals with less NCCs, such as Tcof1-mutant model 
mouse for Treacher Collins syndrome (Dixon and others, 2006). 
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Figure legends 
Fig. 1. Increase of neural crest cells by PHD inhibitors in vivo.  
DMSO controls (A,F) shows all three streams are well established (white arrows). IOX2 
(B-E) or CCT1 (G-J) treated embryos also show all migrations streams present. Black 
arrows show increased Sox10-positive cells. In C,E and J the incidence of sustained 
induction of NCC from the dorsal aspect of the neural tube is observed (arrowheads), 
as seen in our previous study (Scully et al., 2016). The stacked column chart (K-M) 
indicates how the embryos were affected, with an increase (black) in NCC, comparable 
to controls (white) or decrease in NCC and/or toxic to embryos (grey). The highest 
concentration of both IOX2 and CCT1 (0.8mM) does not necessarily further the 
increase (black), rather, it shows underdevelopment of embryos and toxicity (grey). 
For IOX2 (K, 0.3mM n=15, 0.4mM n=10, 0.8mM n=7), the optimum concentration is 
shown to be 0.3mM as the highest incidence of the increase of NCCs. 0.2mM 
concentration for IOX2 was omitted due to a small sample size (n=1). For CCT1 (L, 
0.2mM n=3, 0.3mM n=10, 0.4mM n=17, 0.8mM n=5), the optimum concentration was 
concluded to be 0.4mM. DMOG was tested only at the concentration of 2mM (M, 
n=11). Scale bar in J, 200 µm. 
 
Fig. 2. Vasculature development one day after PHD inhibitor application.  
Embryos were treated with DMSO, DMOG, IOX2 and CCT1 at HH5-6, injected with 
LCA and fixed at HH12 or 13. The heart was removed at vitelline veins (the cut end is 
indicated by asterisks) and arteries proximal to the heart. Embryos were either whole 
mounted (A-D) or cut into sagittal halves and flat-mounted (E-H). Bright field and dark 
field are shown. 
(A-D) HH12, dorsal view. Right and left dorsal aortae (DA) have developed and a sign 
of fusion (arrow) is seen at the level of vitelline veins (DMSO, n=0/4; DMOG, n=4/10; 
IOX2, n=3/6; CCT1, n=1/3). Scale bar; 200 µm. 
(E-H) HH13, lateral view. The mesencephalon (Mes) and diencephalon (Di) have 
developed cephalic plexus, which is more advanced in embryos treated with DMOG 
(n=3), IOX2 (n=7) or CCT1 (n=3) compared to the ones with DMSO (n=5). Scale bar; 
200 µm. 
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Fig. 3. Vasculature development three days after PHD inhibitor application.  
Embryos were treated with DMSO, DMOG, IOX2 and CCT1 at HH5-6, injected with 
LCA and fixed at HH25. The cephalic, pharyngeal and trunk regions are shown as 
indicated. (A,F,K) show lower magnification of DMSO-treated embryos, with rectangles 
indicating the area shown in (B,G,L). In all embryos, vessels and capillaries have 
developed in a similar degree at the cephalic and pharyngeal regions (DMSO, n=10; 
DMOG, n=12; IOX2, n=3; CCT1, n=4). Whereas in the trunk region, more vessels are 
seen in segments between intersomitic vessels in drug-treated embryos compared to 
DMSO-treated embryos (DMOG, n=12/12; IOX2, n=3/3; CCT1, n=3/4). Tel, 
telencephalon; Di, diencephalon; Mes, mesencephalon; ba1 and ba2, branchial arch 
1 and 2. Arrowheads show three segments divided by intersomitic vessels. Scale bars; 
500 µm. 
 
 
Fig. 4. Advanced development of the otic capsule in PHD inhibitor-treated 
embryos.   
(A-F) A chronological series of Alcian blue-stained embryos at HH29-33 depicting the 
increasing complexity of the otic capsule in DMSO treated embryos, with schematic 
drawings below. The rectangle in (A) is the area magnified in (B). During the stages 
HH29-33 (E6-8), the dorsal aspect of the otic capsule becomes defined as the superior 
outpouch develops, whereas in the anterior aspect the horizontal outpouch elongates 
and posteriorly the posterior outpouch develops the curvature. a, anterior; d, dorsal; l, 
lateral; post, posterior outpouch; sup, superior outpouch; hor, horizontal outpouch; cd, 
cochlear duct.  
(G-I) Embryos at HH30, treated with PHD inhibitors as indicated at HH5-6. Two 
examples are shown for each treatment. Well-defined otic capsules resemble HH31-
32; in particular in horizontal and posterior outpouches. Advanced outpouches 
compared to DMSO were seen in; DMOG, n=8/8; IOX2, n=9/9; CCT1, n=4/4. 
(J-M) Embryos at stage HH31, treated with PHD inhibitors as indicated at HH26. Two 
examples are shown for each treatment. Outpouches are more well defined in drug-
treated embryos (K-M) compared to the control (J). Advanced outpouches compared 
to DMSO were seen in; DMOG, n=5/5; IOX2, n=9/9; CCT1, n=7/7. 
 
 
Fig. 5. Deformed otic capsules after PHD inhibitor treatment  
(A-H) Three-Dimensional reconstructions of the otic capsule (blue) and inner ear 
(green) of 10-day-old chick embryos (HH36) after DMSO or PHD inhibitor treatment, 
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posterior (A,C,E,G,I) and left posterior oblique (B,D,F,H) views. The DMSO control 
(A,B) shows a tall and wide otic capsule, with a large foramen magnum in the centre. 
In DMOG-treated embryos (C,D) the height of the otic capsule is reduced. This has in 
turn lead to the distortion of the inner ear within the otic capsule, as shown in Fig. 5. 
The height of the otic capsule in IOX2 (E,F) and CCT1 (G,H) -treated embryos does 
not appear affected (E-H). The maximum width of the otic capsule (indicated by white 
arrow in I) was quantified in 6 embryos from each group, resulting in graph J. The width 
of the otic capsule was relatively reduced in DMOG or CCT1 treated embryos. A 
statistically significant difference was shown between DMOG and IOX2 (ANOVA, 
P=0.027). The bars show the mean of 6 embryos and the error bars show standard 
deviation. 
 
 
Fig. 6. Deformed semicircular canals after PHD inhibitor treatment  
 Three-Dimensional reconstructions of the inner ear of 10-day-old chick embryos 
(HH36) after DMSO or PHD inhibitor treatment, posterior (A,C,E,G) and left-posterior 
oblique views (B,D,F,H). Semicircular canals (a, anterior; l, lateral; p, posterior) and 
cochlear duct (c) are indicated. In DMOG-treated embryo, the height of the anterior 
semicircular canal is noticeably reduced (C,D, double arrowhead). In IOX2 or CCT1-
treated embryos, the semicircular canals are strikingly thinner and discontinuous (E-
H, arrowheads). The cochlear duct is kept intact in all cases. (I,J) Left lateral views 
showing the orientation and measurement for the distance between the ampulla and 
the tallest aspect of the anterior semicircular canal (measured in 3D) used for (K). 
Graph (K) shows the result of 6 embryos (12 sides) for each of the four groups. The 
difference in height was statically significantly different between DMSO and DMOG 
(P=0.005) and DMOG and IOX2 (P=0.011) in ANOVA analyses. CCT1 also appeared 
affected but statistically not quite significant (P<0.1). The bars show the mean of 12 
anterior semicircular canals from 6 embryos and the error bars show standard 
deviation. 
 
 
Fig. 7. Coronal CT image of the maxilla in 10-day-old chick embryos after 
application of PHD inhibitors 
(A-D) shows coronal section including the maxilla and mandible, including the internal 
naris, a slit between bilateral palatine processes (see arrows in E for the position). 
Embryos treated with PHD inhibitors show similar size of internal naris (B-D) compare 
to DMSO control (A). (E) shows a magnified image of the maxilla with internal naris 
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(arrow). The size of the slit was quantified, and graph (F) was produced from data of 6 
embryos of each group. (F) shows that the size of internal naris was not altered through 
application of PHD inhibitors, assessed by ANOVA. The error bars show standard 
deviation. 
 
 
 
 
 
 
 
 
 
 
